Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | PGK1 | P00558 | 2/20 | 0.32 |
| ▸ | PGK2 | P07205 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322447 | 0.68 | — | — | |
| SCHEMBL171079 | 0.67 | PTPN1 (0.38) | PTPN1PGK1PGK2 | |
| SCHEMBL1012634 | 0.65 | DGAT1 (0.42) | GAA | |
| SCHEMBL18116696 | 0.64 | DGAT1 (0.33) | GAA | |
| SCHEMBL11207116 | 0.64 | DGAT1 (0.33) | GAA | |
| SCHEMBL8669260 | 0.64 | DGAT1 (0.38) | GAA | |
| SCHEMBL4812438 | 0.64 | PTPN1 (0.36) | PTPN1PGK1PGK2 | |
| SCHEMBL1938870 | 0.63 | — | — | |
| SCHEMBL992 | 0.63 | DGAT1 (0.41) | PTPN1PGK1PGK2 | |
| SCHEMBL16863947 | 0.63 | GAA (0.47) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012098-B2 | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers | PHARMACIA CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1463495-A4 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1528921-A2 | METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS | Pharmacia Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1506040-A2 | SELECTIVE INOS INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1505972-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1463495-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040127569-A1 | Methods for treatment and prevention of gastrointestinal conditions | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| EP-1429752-A1 | NEUROPROTECTIVE TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | Pharmacia Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004012726-A2 | METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS | PHARMACIA CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003097163-A2 | USING A SELECTIVE INOS INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097050-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030119826-A1 | Neuroprotective treatment methods using selective iNOS inhibitors | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030109522-A1 | Ophthalmologic treatment methods using selective iNOS inhibitors | PHARMACIA CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6545170-B2 | For therapy of rheumatoid arthritis and in osteoarthritis, inflammatory bowel disease, cardivascular ischemia, diabetes, congestive heart failure, myocarditis, atherosclerosis, migraine, glaucoma, aortic aneurysm, reflux esophagitis | PHARMACIA CORPORATION | 2003-04-08 | — | — | US | disclosed |
| WO-2003026638-A1 | NEUROPROTECTIVE TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030013702-A1 | Agents and methods for treatment of cancer | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020143061-A1 | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors | PITZELE BARNETT S (US) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013702-A1 | Agents and methods for treatment of cancer | FAP, APC, PTGIS | PTPN1 1539/4885PGK1 1660/4885PGK2 1083/4885 |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | PTPN1 3997/4885PGK1 2442/4885PGK2 1944/4885 |
| US-20040127569-A1 | Methods for treatment and prevention of gastrointestinal conditions | SI, NOS2, NOS3 | PTPN1 2984/4885PGK1 1182/4885PGK2 1375/4885 |
| US-20030109522-A1 | Ophthalmologic treatment methods using selective iNOS inhibitors | NOS2, NOS1, NOS3 | PTPN1 3701/4885PGK1 1402/4885PGK2 1299/4885 |
| US-20030119826-A1 | Neuroprotective treatment methods using selective iNOS inhibitors | NOS2, NOS1, NLN | PTPN1 4141/4885PGK1 2133/4885PGK2 2135/4885 |
| US-20020143061-A1 | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, NOS1, NOS2 | PTPN1 2923/4885PGK1 1266/4885PGK2 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.